Target：ING5
Gene Name：ING5
Protein Name：Inhibitor of growth protein 5 (p28ING5)
Human Gene Id：84289
Human Swiss Prot No：Q8WYH8
Mouse Swiss Prot No：Q9D8Y8
Immunogen：Synthesized peptide derived from part region of human protein
Specificity：ING5 Polyclonal Antibody detects endogenous levels of protein.
Formulation：Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
Source：Polyclonal, Rabbit,IgG
Dilution：WB 1:500-2000 ELISA 1:5000-20000
Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration：1 mg/ml
Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)
Observed Band(KD)：26kD
Background： This gene encodes a tumor suppressor protein that inhibits cell growth and induces apoptosis. This protein contains a PHD-type zinc finger. It interacts with tumor suppressor p53 and p300, a component of the histone acetyl transferase complex, suggesting a role in transcriptional regulation. Alternative splicing and the use of multiple promoters and 3' terminal exons results in multiple transcript variants. [provided by RefSeq, Aug 2016],
Function：function:Component of the HBO1 complex which has a histone H4-specific acetyltransferase activity, a reduced activity toward histone H3 and is responsible for the bulk of histone H4 acetylation in vivo. Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. Through chromatin acetylation it may regulate DNA replication and may function as a transcriptional coactivator.,similarity:Belongs to the ING family.,similarity:Contains 1 PHD-type zinc finger.,subunit:Component of the HBO1 complex composed at least of ING4 or ING5, MYTS2/HBO1, EAF6, and one of PHF15, PHF16 and PHF17. Component of the MOZ/MORF composed at least of ING5, MYST3/MOZ, MYST4/MORF and one of BRPF1, BRD1/BRPF2 and BRPF3. Interacts with EP300 and TP53.,
Subcellular Location：Nucleus . Chromosome . Localizes to transcription start sites. .
Expression：Down-regulated in bone marrow cells in acute myeloid leukemia patients as compared with normal bone marrow cells.
